Hong Kong Lemite Group Limited
Retatrutide
Finnrick tested 4 samples of Retatrutide (GLP-1, GIP, and GCGR agonist) from Hong Kong Lemite Group Limited between 17 Dec 2025 and 7 Mar 2026. Test scores average below 4 or some scores below 3, and at least 2 tests, warrant a tentative Finnrick Rating of E (Bad).
Finnrick Rating™
Tentative Rating
Hong Kong Lemite Group Limited
Retatrutide
Tested 4 Samples
Last test 7 Mar 2026
Take Action
Free peptide testing
Mail in a sample (US only) to get confidence for the specific vials you have, and contribute to identifying unsafe supply chains, so other people can avoid risky and costly mistakes.
Other Retatrutide tests from top-rated vendors:
All Retatrutide tests from Hong Kong Lemite Group Limited
Samples are tested in commercial labs
Tests Count
4
Scores
AVGMINMAX
Last
7 Mar 2026
First
17 Dec 2025
| Quantity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 7 Mar 2026 | View | 20mg | 19.9mg | -0.5% | 99.70% | 2026R20A104 | White Label / Silver Crimp / Green Cap | Lab G | Public | |
| 6 Mar 2026 | View | 10mg | 8.23mg | -17.7% | 99.90% | Ax12032001 | No Label / Silver Crimp / White Cap | Lab E | Public | |
| 29 Dec 2025 | View | 30mg | 7.28mg | -75.7% | 98.92% | (no batch ID) | White Label / Silver Crimp / Pink Cap | Lab E | Public | |
| 17 Dec 2025 | View | 10mg | 8.54mg | -14.6% | 99.95% | SART1020250728L | No Label / Silver Crimp / Blue Cap | Lab E | Public | |